Longeveron Set to Present at the Emerging Growth Virtual Conference
MIAMI – Longeveron Inc. (NASDAQ: LGVN), recognized for its trailblazing efforts in developing cutting-edge cellular therapies, is set to take part in the Emerging Growth Virtual Conference. This conference spans multiple days, offering a platform for innovative firms to connect with potential investors and stakeholders.
Conference Details
Key Information About the Presentation
Longeveron will deliver a presentation during the conference on February 19, 2025. The presentation is scheduled from 3:10 to 3:20 p.m. ET, where Longeveron's leadership will delve deep into its innovative approaches and dedicated research in regenerative medicine.
Attendees can access the conference webcast through the "Events and Presentations" section on the Company's website. Following the event, a replay of the presentation will be accessible on Longeveron’s platform for 180 days, allowing plenty of time for those who couldn’t attend to catch up on the insights shared.
The Heart of Longeveron
About the Company
Longeveron Inc. stands at the forefront of clinical stage biotechnology, devoted to pioneering regenerative medicines that respond to significant unmet medical needs. Its flagship product is Lomecel-B™, an innovative therapy derived from the bone marrow of young, healthy adults.
The mechanism of action behind Lomecel-B™ is diverse; it promotes vascular health, tissue repair, and has anti-inflammatory properties, promising potential across a range of diseases. Currently, Longeveron is focused on advancing its product through three primary clinical indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.
Recognition and Designations
Regulatory Advancements
Lomecel-B™ has garnered significant attention from regulatory bodies, leading to five distinct designations from the FDA. These include Orphan Drug designation and Fast Track designation for the HLHS program, and both Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation for the Alzheimer’s disease program.
These recognitions reflect the potential impact of Longeveron’s therapies and the urgent need for innovative solutions in these critical medical areas. Investors and stakeholders can look forward to insights on these developments during the conference.
Engagement Opportunities
Interaction and Queries
Participants in the conference are encouraged to engage actively. Questions can be sent ahead of time to the designated email or can be asked live during the session, providing an excellent opportunity for in-depth dialogue between the company’s representatives and the audience.
Contact Information
Investor Relations and Media Contact
For further inquiries, you can reach out to Derek Cole from Investor Relations Advisory Solutions via email. He is available to handle media and investor-related questions effectively.
Frequently Asked Questions
What is Longeveron known for?
Longeveron is a clinical-stage biotechnology company specializing in regenerative medicines, particularly focusing on cellular therapies.
When is the Longeveron presentation at the conference?
The presentation is scheduled for February 19, 2025, from 3:10 p.m. to 3:20 p.m. ET.
How can I access the conference presentation?
You can access the presentation online through the “Events and Presentations” section of Longeveron’s website, where a replay will be available afterward.
What are the main diseases Longeveron is targeting?
Longeveron is focused on treating hypoplastic left heart syndrome, Alzheimer’s disease, and Aging-related Frailty through its innovative therapies.
Who can I contact for more information?
You can contact Derek Cole at Investor Relations Advisory Solutions for any inquiries related to the conference or Longeveron's offerings.
